Home Tags Camidanlumab tesirine

Tag: camidanlumab tesirine

Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced...

Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for...

ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for...

This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for patients with hematological malignancies and...

FDA Lifts Partial Clinical Hold on Pivotal Phase II Clinical Trial...

Earlier this week the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on the pivotal Phase II clinical study of camidanlumab...
New York Stock Exchange (released under Public Domain license. Photo courtesy 2020 Jean Beaufort.

ADC Therapeutics Completes U.S. $ 267 Million Initial Public Offering

Earlier today, New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, confirmed that ADC Therapeutics (Lausanne; Biopôle, Switzerland),...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R...

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in the study and treatment of...

What is Pyrrolobenzodiazepine (PBD)?

Structure of Pyrrolobenzodiazepine Pyrrolobenzodiazepine (PBD) Chemical Name: Diazepinoindole; Molecular Formula: C14H14N2O3 Molecular weight: 258,27 g/mole Average mass: 181.193 Da Monoisotopic mass: 181.063995 DaIntroduction Discovered in 1963, the pyrrolobenzodiazepines (PBDs) are a class of...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...

Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...